'Progression free' presentation slideshows

RTP TV: An 8-Part Live CME Webcast Series

913 views • 78 slides

Outline

Drivers Oncogenetici Nel NSCLC: Impatto Nella Pratica Clinica Presente e Futura Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK. Outline. Molecular events in NSCLC Beyond EGFR and ALK Conclusions.

573 views • 57 slides

595 views • 43 slides

Keith T. Flaherty, MD Assistant Professor of Medicine Abramson Cancer Center of the

Clinical Updates Novel Agents for the Treatment of Metastatic Melanoma Future Directions: Opportunities for Targeting B-RAF and Other Targets in Melanoma Management. Keith T. Flaherty, MD Assistant Professor of Medicine Abramson Cancer Center of the University of Pennsylvania

598 views • 42 slides

Challenges in the Treating of Bone and Soft Tissue Sarcomas

Challenges in the Treating of Bone and Soft Tissue Sarcomas. Margaret von Mehren, MD Director Sarcoma Oncology Fox Chase Cancer Center Philadelphia, PA. Definition of Sarcomas.

849 views • 39 slides

354 views • 16 slides

T. Gruenberger*, H. Sorbye, M. Debois, U. Bethe, J. Primrose,

Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM) Interim results of the EORTC Intergroup randomized phase III study 40983. T. Gruenberger*, H. Sorbye, M. Debois, U. Bethe, J. Primrose,

259 views • 15 slides

Spigel DR et al. Proc ASCO 2011;Abstract 7505.

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC. Spigel DR et al. Proc ASCO 2011;Abstract 7505. Introduction.

278 views • 9 slides

Datko F et al. Proc SABCS 2012; Abstract P5-18- 20.

A Phase II Study of Pertuzumab , Trastuzumab , and Weekly Paclitaxel in Patients with HER2 - Overexpressing Metastatic Breast Cancer. Datko F et al. Proc SABCS 2012; Abstract P5-18- 20. Background.

311 views • 9 slides

Ardeshna KM et al. Proc ASH 2010 ; Abstract 6.

An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma. Ardeshna KM et al. Proc ASH 2010 ; Abstract 6. Eligibility. Follicular lymphoma Grade 1, 2, 3a Stage II, III, IV

213 views • 8 slides